Alzheimer’s News Today

Alzheimer's News Today is an online news platform focused on providing thorough daily updates about Alzheimer's Disease.

International

English

Online/Digital

Outlet metrics

Domain Authority

Ranking

Global

#1293984

United States

#632588

Health/Health Conditions and Concerns

#1825

Traffic sources

Monthly visitors

Articles

Alzheimer's Association urging 'action now' for awareness month

3 weeks ago | alzheimersnewstoday.com | Marisa Wexler

June is Alzheimer’s and Brain Awareness Month, and the Alzheimer’s Association is urging patients, caregivers, and supporters to “take action now — for yourself, your loved ones, and for the fight to end Alzheimer’s.”The U.S.-based nonprofit is taking to social media and hosting both virtual and in-person events throughout the month to raise awareness about Alzheimer’s disease and other forms of dementia.
ApoE4 Alzheimer's Alliance launched as US advocacy group

1 month ago | alzheimersnewstoday.com | Andrea Lobo

A new patient advocacy organization, the ApoE4 Alzheimer’s Alliance, has launched in the U.S., with a goal of helping advance both supportive policies and the development of treatments for people with Alzheimer’s disease associated with the ApoE4 gene variant. According to the National Institutes of Health, this variant of the Apoe gene is one of the strongest genetic risk factors for Alzheimer’s among individuals of European descent.
Leqembi approved in EU as treatment for early Alzheimer's

2 months ago | alzheimersnewstoday.com | Lindsey Shapiro

Leqembi (lecanemab) has won marketing authorization in the European Union for the treatment of certain adults with early Alzheimer’s disease, making it the first therapy that targets an underlying cause of the neurodegenerative condition to be approved in the region. The treatment is indicated for adults with mild cognitive impairment or mild dementia due to Alzheimer’s who have confirmed buildup in the brain of the amyloid-beta protein — the disease hallmark that Leqembi targets.
Simufilam fails to meet Alzheimer's Phase 3 trial goals; to be discontinued

2 months ago | alzheimersnewstoday.com | Margarida Maia

Cassava Sciences will discontinue developing simufilam for mild to moderate Alzheimer’s disease by the end of the second quarter of this year after the experimental treatment failed to meet key Phase 3 trial goals for improving cognition and daily function.
Menopause, synapse health may interact to raise Alzheimer's risk

Mar 7, 2025 | alzheimersnewstoday.com | Lindsey Shapiro |Ray Burow |Mary Chapman |Patricia Inacio

Age at menopause may interact with factors related to the health of synapses, or nerve cell connections, to influence the risk of Alzheimer’s disease in women, a study found. Associations between biomarkers of poor synapse health and higher levels of Alzheimer’s-related proteins in the brain, as well as steeper cognitive declines, were stronger when menopause was experienced at a younger age, the researchers said.
Leqembi IV monthly maintenance dosing approved by FDA

Feb 7, 2025 | alzheimersnewstoday.com | Andrea Lobo |Ray Burow |Margarida Maia |Lindsey Shapiro

The U.S. Food and Drug Administration (FDA) has approved monthly maintenance dosing for Leqembi (lecanemab), a treatment for early Alzheimer’s disease. The decision follows a supplemental application from Eisai, which is codeveloping Leqembi with Biogen, based on the modeling of data from the Phase 2 Study 201 (NCT01767311) and the Phase 3 Clarity AD study (NCT03887455), and their long-term extension studies, showing that once-monthly dosing can help sustain the therapy’s beneficial effects.
The extra tasks when caregiving in a cold climate

Jan 27, 2025 | alzheimersnewstoday.com | Ray Burow |Marisa Wexler

“I’ve never been so cold in my life.”I recently visited Washington, D.C., and it was cold — perhaps not by the standards of northern states, but bitter compared with my home in South Florida. Now, I’ve been colder in my life, but the quotation above pumped through my mind while I was there, prompting a warm memory of my mother. She said those words early in her dementia journey and my caregiving adventure when, a year or so after my father’s passing, his only brother passed away, too.
The holidays can be challenging for an Alzheimer's caregiver

Dec 9, 2024 | alzheimersnewstoday.com | Ray Burow

Like most people, caregivers look forward to celebrating the holidays with family and friends. Or do they? Christmas is a wonderful time of year, but it carries many expectations, with the greatest being to fulfill the holiday spirit. We want to have and share that warm, fuzzy feeling that accompanies Hallmark Christmas cards and movies. Weeks before Christmas, visions of rolling out Christmas cookies, entertaining carolers, and attending Christmas Eve church services dance in our heads.
Modified Kisunla dosing lowers risk of ARIA-E in Alzheimer’s: Study

Nov 8, 2024 | alzheimersnewstoday.com | Margarida Maia |Lindsey Shapiro |Steve Bryson

Being started on a smaller dose of the approved early Alzheimer’s disease therapy Kisunla (donanemab) — by shifting one vial from the first to the third infusion treatment — reduces the risk of ARIA-E, or amyloid-related imaging abnormalities associated with brain swelling, among adults with the neurodegenerative condition.
The loss of a friend brings back bittersweet memories of my parents

Nov 4, 2024 | alzheimersnewstoday.com | Ray Burow

Both of my parents, Ruth and Jim Page Sr., have passed from this life to the next. They were tremendous people who loved each other and their children profoundly. They had many gifts, separately and together. I’ve never met two people whose gifts, talents, and interests were so well matched. Ray Burow’s parents, Ruth and Jim Page Sr., enjoyed entertaining friends at their West Virginia home.